Anti-BTLA(tifcemalimab biosimilar) mAb Cat. No. BME100695



PRODUCT INFORMATION

Uniprot ID)	Q7Z6A9
Common	Name	lcatolimab;JS-004;JS004;JS 004;JS-4;JS4;JS 4;TAB-004;TAB004;TAB 004;TAB-4;TAB4;TAB 4
Conjugate	9	Unconjugated
Synonym	5	BTLA;BTLA1;CD272
Applicatio	ons	N/A
Recomme Dilutions	nded	N/A
Formulati Reconstit		Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Spec	ies	N/A
lgG type		lgG4
Reactivity	/	Human
Target		BTLA
Descriptio	on	Anti-BTLA(tifcemalimab biosimilar[]lgG4) mAb
Delivery		3-4 weeks
Storage &	α Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. Research grade biosimilar. Not for use in
Backgrou	nd	therapeutic or diagnostic procedures for humans or animals.
Usage		Research use only
DIMA Disc	claimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

Email: info@dimabio.com Website: www.dimabio.com

